Market Size of Global Joint Pain Injections Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Joint Pain Injections Market Analysis
Joint Pain Injections Market is expected to register a growth at a CAGR of 6% over the forecast period.
The COVID-19 pandemic restrictions affected the diagnosis and treatment of chronic diseases worldwide impacting the studied market. For instance, according to a research article titled "COVID-19 and Rheumatoid Arthritis" published in May 2021, older patients with rheumatoid arthritis (RA) were susceptible to COVID-19. RA patients had been affected by changes in access to care, telemedicine, drug shortages, anxiety, and social isolation, which contribute to disease flares. During the pandemic, access to therapy was constrained. 42% of patients reported canceled/postponed appointments and switched to telemedicine visits. Hence, COVID-19 had an adverse impact on the joint pain infection market.
In addition, the growing prevalence of arthritis and increasing geriatric population worldwide, and the increasing demand for knee pain injections are actively affecting the growth of the studied market.
According to World Population Prospects 2022 report, the percentage of the population aged 65 years and over in Sub-Saharan Africa is 3.0 in 2022 and projected to be 3.3 in 2030, in Northern Africa and Western Asia it is estimated to be 5.5 in 2022 and projected to be 7.0 in 2030, in Central and Southern Asia it is estimated to be 6.4 in 2022 and projected to be 8.1 in 2030, and in Europe and Northern America, 18.7 in 2022 and projected to be 22.0 in 2030. Since arthritis is more common in the geriatric population, the growth of the market segment is likely to increase as this population increases.
Furthermore, as per the Centers for Disease Control and Prevention's October 2021 update, 43% of osteoarthritis patients were 65 years of age or older in 2020. It also stated that the annual incidence of knee osteoarthritis is highest between 55 and 64 years old. More than half of individuals with symptomatic knee osteoarthritis are younger than 65. The surge in the geriatric population is expected to increase the burden of osteoarthritis and other disorders which is likely to augment the growth of the studied market over the forecast period.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. however, the high costs of the injections and reimbursement issues are likely to impede the market growth.
